GlycoEra
GlycoEra is a biotechnology research company that produces extracellular protein degraders for the treatment of autoimmune diseases. It leverages its proprietary CustomGlycan platform to design biologics that selectively target and degrade disease-causing proteins, such as autoantibodies, without broadly suppressing the immune system. The company's lead program, GE8820, is engineered to degrade pathogenic IgG4 autoantibodies with high specificity and efficiency, addressing conditions like pemphigus, muscle-specific kinase (MuSK) myasthenia gravis, primary membranous nephropathy, and autoimmune encephalitis. This approach offers the potential for earlier intervention and improved patient outcomes compared to existing therapies.
Domain
glycoera.com
Country
SwitzerlandIndustry
BiotechnologyEmployees
11-50
Last Funding
$130.0M
Founded
2019
Tech Stack (16 technologies)
Frequently Asked Questions
What technologies does GlycoEra use?+
GlycoEra uses 16 technologies including Contact Form 7, WP Job Openings, WordPress.
What industry is GlycoEra in?+
GlycoEra operates in the Biotechnology industry.
Where is GlycoEra based?+
GlycoEra is headquartered in Switzerland.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026